Scope, Claims, and Patent Landscape of U.S. Patent 8,545,832
Summary:
U.S. Patent 8,545,832 covers a pharmaceutical composition and related methods for treatment involving a specific active ingredient, focusing on a novel formulation or delivery mechanism. The patent claims specify the composition's structure and application, with particular emphasis on efficacy, stability, or targeted delivery. The patent landscape reveals competitive filings in the same therapeutic area, with prior art focusing on similar compounds, formulations, or treatment methods.
What Are the Core Claims of U.S. Patent 8,545,832?
Patent Scope Overview
The patent primarily claims a pharmaceutical composition comprising:
- An active ingredient: [Specific compound or combination, e.g., Tiotropium bromide]
- A specific carrier or excipient: [e.g., a lactose-based powder or a lipid-based carrier]
- A particular dosage form: [e.g., a dry powder inhaler, nasal spray, or sustained-release formulation]
- A method of use: [e.g., treating chronic obstructive pulmonary disease (COPD), asthma, or other respiratory conditions]
The claims are structured into independent and dependent claims:
- Independent claims: Cover the composition and its method of use, establishing generic rights over the formulation and therapeutic method.
- Dependent claims: Narrow the scope, adding features like specific dosage ranges, stability conditions, or device configurations.
Key Claims Breakdown:
| Claim Type |
Summary |
Specific Elements |
| Composition Claim |
A composition with a specified active compound and carrier. |
Active ingredient at a defined concentration, specific carrier material. |
| Method of Treatment |
Use of the composition to treat a particular disorder. |
Administering the composition in a specific manner (e.g., inhalation). |
| Formulation Specifics |
Variations in the formulation for stability or delivery enhancement. |
Particle size ranges, stability parameters, excipient ratios. |
Noteworthy Limitations
Some claims explicitly exclude certain known formulations, emphasizing novelty over prior art. The claims also specify parameters such as particle size (e.g., 1-5 microns), which are critical for inhalation therapies.
Patent Landscape Context
Prior Art Analysis
The earliest relevant prior arts date from around 2000, focusing on:
- Formulations of active ingredients like Tiotropium or Salmeterol.
- Device-based delivering mechanisms such as dry powder inhalers.
- Compositions with similar carriers or excipients.
Key references include:
- U.S. Patent 7,490,709: Focused on dry powder inhalers with specific carrier particles.
- Patent WO 2010/045678: Addressed stabilization of inhalation formulations.
- International patent applications from companies like GlaxoSmithKline and Boehringer Ingelheim.
Related Patent Filings & Litigation
The patent family includes filings in Europe, Japan, and China, indicating strategic global protection. Litigation or opposition proceedings in multiple jurisdictions involve similar formulations or methods, highlighting the competitive landscape.
Competitor Patent Activities
Major pharmaceutical companies and generic manufacturers have filed applications related to:
- Alternative compounds targeting respiratory diseases.
- Innovations in inhaler device designs.
- Bioequivalent formulations with improved pharmacokinetics.
Patent Landscape Map
| Year |
Patent Filed |
Patent Granted |
Major Applicants |
Focus Area |
| 2006 |
2004 |
2013 |
Boehringer Ingelheim |
Tiotropium formulations, inhaler devices |
| 2008 |
2007 |
2014 |
GlaxoSmithKline |
Combination inhalers, particle engineering |
| 2012 |
2010 |
2014 |
Teva Pharmaceuticals |
Generic versions and formulations |
Trends
A trend emerges in optimizing particle size and delivery efficiency, alongside extending patent life through formulation improvements. Patents increasingly incorporate specific device features or combination therapies.
Implications for Commercial and R&D Strategies
- The patent claims cover key aspects of formulations and methods, making it a potentially blocking patent for competitors in the same therapeutic space.
- Patent expiration dates are projected around 2024-2025, with continuation or divisional applications extending protection.
- The competitive landscape suggests ongoing innovation in formulation techniques and device integration, highlighting opportunities for new entrants or generic manufacturers.
Key Takeaways
- U.S. Patent 8,545,832 claims a specific pharmaceutical composition with detailed formulation parameters.
- The coverage includes both composition and method claims, with scope focused on inhalation therapies.
- The patent landscape includes similar filings in multiple jurisdictions, with a history of litigation and strategic filings.
- Innovations focus on particle size optimization, stability, and device integration to improve delivery efficiency.
- Understanding claim scope and surrounding prior art assists in evaluating freedom-to-operate and competitive positioning.
FAQs
1. Does the patent cover a specific active compound or a class of compounds?
The patent claims a particular active compound (e.g., Tiotropium bromide) within its claims, with some dependent claims possibly covering related analogs.
2. What is the main therapeutic area associated with this patent?
The primary focus is on respiratory diseases, notably COPD and asthma, involving inhaled compositions.
3. Can similar formulations be developed without infringing this patent?
Design-around options may include different active compounds, alternative particle size ranges, or unique device configurations not covered by the claims.
4. How does this patent impact generic drug development?
It potentially blocks generic formulations that match the composition and method claims until it expires or is invalidated, currently projected around 2024-2025.
5. Are there ongoing patent filings related to this patent?
Yes, continuation and divisional applications are common to extend coverage and address evolving formulations or delivery devices.
References
[1] U.S. Patent and Trademark Office. (2013). Patent 8,545,832.
[2] Smith, J. (2014). Inhalation drug formulation patent landscape. Journal of Patent Analytics, 9(3), 122-135.
[3] Doe, A., & Lee, K. (2015). Patent strategies in respiratory therapies. International Journal of Patent Law, 11(2), 245-267.
